Rapport Therapeutics, Inc.

As of June 30, 2026, Rapport Therapeutics, Inc. carries a market capitalization of 2.00B, placing it among publicly traded companies globally. Its enterprise value stands at 1.57B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Rapport Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Rapport Therapeutics, Inc. has 47.96M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 93.56, and the price-to-book ratio stands at 4.72.

These figures are as of June 30, 2026. The EV/Sales ratio of 78.62 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.57B versus a market cap of 2.00B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Rapport Therapeutics, Inc. maintains a current ratio of 15.72, meaning it holds 15.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Rapport Therapeutics, Inc. posted a negative return on equity (ROE) of -39.96, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -36.85, reflecting losses generated across the asset base. The company generates approximately 249,221.18 in revenue per employee across its workforce of 80.25, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Rapport Therapeutics, Inc.'s stock has gained approximately 6.55% over the past 52 weeks. The 50-day moving average sits at 39.48, while the 200-day moving average is 35.74.

Over the twelve months ended June 30, 2026, Rapport Therapeutics, Inc. generated 20.00M in revenue and converted that into -137.16M in net income, yielding earnings per share of -3.05. EBITDA reached -152.56M, while operating income came in at -153.52M.

As of June 30, 2026, Rapport Therapeutics, Inc. holds 436.08M in cash and equivalents against 10.11M in total debt, resulting in a net debt position of -63.61M. Total book value stands at 422.93M, with working capital of 418.43M providing operational flexibility.

Rapport Therapeutics, Inc. produced -96.68M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -467,000.00 in capital expenditures, free cash flow totaled -97.15M - equivalent to -2.16 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -767.58 and net profit margin of -685.80 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -5.19: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -13.65, meaning Rapport Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Rapport Therapeutics, Inc. has an Altman Z-Score of 32.34, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.